The antithrombin activity test checks how well antithrombin, one of the body’s natural clot-control proteins, is working. Antithrombin slows down clotting by blocking thrombin and factor Xa, two enzymes that help form fibrin, the mesh that stabilizes a blood clot. When antithrombin activity is too low, blood clots more easily, especially in the deep veins of the legs or the lungs.
Doctors usually order this test after an unexplained or repeated venous blood clot, a clot at a young age, a strong family history of clots, or poor response to heparin. A low result does not always mean an inherited deficiency. Antithrombin can fall temporarily during acute illness, active clotting, heparin treatment, liver disease, kidney protein loss, major surgery, pregnancy complications, or disseminated intravascular coagulation. Because timing changes the result, abnormal antithrombin activity often needs repeat testing when the person is stable and off interfering medicines.
- Antithrombin activity measures function, not just amount. It shows how well antithrombin blocks clotting enzymes, usually reported as a percentage of normal activity.
- A typical adult reference range is about 80% to 120% or 80% to 130%. Each lab sets its own range, and infants normally have lower levels than adults.
- Low antithrombin raises venous clot risk. It is linked most strongly with deep vein thrombosis and pulmonary embolism, not routine arterial heart attack screening.
- Low results need context. Acute thrombosis, heparin therapy, liver disease, nephrotic syndrome, severe infection, DIC, and major surgery can lower antithrombin without an inherited disorder.
- Inherited antithrombin deficiency is uncommon but high risk. Family testing and prevention during surgery, pregnancy, hospitalization, or long immobility may be important.
- Heparin needs antithrombin to work well. Low antithrombin can contribute to heparin resistance, especially in intensive care, cardiac surgery, or extracorporeal circulation settings.
Table of Contents
- What the Antithrombin Activity Test Measures
- When the Test Is Ordered
- Normal Range and Result Patterns
- Causes of Low Antithrombin Activity
- Inherited Antithrombin Deficiency
- Antithrombin, Heparin, and Treatment Decisions
- Follow-Up Testing and Next Steps
- Common Mistakes When Reading Results
What the Antithrombin Activity Test Measures
The antithrombin activity test measures how well antithrombin works as a natural brake on clot formation. Antithrombin is a protein made mainly by the liver. It circulates in the blood and helps prevent clotting from spreading beyond the site of injury.
Blood clotting is useful when it seals a cut or injured blood vessel. The problem begins when clots form inside veins without a clear need or grow larger than they should. Antithrombin helps control this process by inactivating several clotting enzymes, especially thrombin and factor Xa.
Thrombin changes fibrinogen into fibrin, which gives a clot strength. Factor Xa helps generate thrombin. By slowing both enzymes, antithrombin reduces excessive clot formation.
This test is called an activity test because it checks function. That matters because a person can have a normal amount of antithrombin protein that does not work properly. In that situation, an antigen test, which measures quantity, may look normal while the activity test is low.
The antithrombin activity test is usually part of a thrombophilia evaluation. Thrombophilia means a tendency to form abnormal clots. Other tests in the same workup may include protein C activity, protein S activity, factor V Leiden screening through activated protein C resistance testing, and antiphospholipid antibody testing.
Antithrombin has a special relationship with heparin. Unfractionated heparin and low molecular weight heparin work by greatly increasing antithrombin’s ability to block thrombin and factor Xa. If antithrombin is very low, heparin may have a weaker effect than expected. This is one reason doctors check antithrombin activity in some people with poor heparin response.
When the Test Is Ordered
Doctors do not order antithrombin activity as a routine screening test for everyone with a blood clot. The test is most useful when the result could change care, explain a strong clotting pattern, or guide prevention for relatives.
Common reasons for testing include:
- A first venous clot before about age 45 to 50, especially without a major trigger
- Recurrent deep vein thrombosis or pulmonary embolism
- A clot in an unusual location, such as the portal, mesenteric, cerebral, or hepatic veins
- A strong family history of venous thromboembolism
- A known antithrombin deficiency in a close relative
- Blood clots during pregnancy, postpartum, or while using estrogen therapy
- Unexpected clotting while receiving heparin
- Difficulty reaching a heparin target on an anti-Xa test or aPTT-based heparin protocol
- Evaluation before high-risk surgery or pregnancy in someone from an affected family
Testing is less helpful during the first days or weeks of a new clot because active thrombosis can consume antithrombin and make the level look lower than the person’s baseline. Testing during hospitalization, severe infection, major surgery, liver failure, nephrotic syndrome, or heparin treatment can also mislead.
Many people with a provoked clot do not need inherited thrombophilia testing. A provoked clot has a clear trigger, such as major surgery, trauma, prolonged hospitalization, or a temporary leg cast. In those cases, the trigger often explains the clot better than a hereditary disorder.
Testing becomes more useful when the clot pattern looks stronger than expected: young age, repeated events, clots in several relatives, or a clot with only a weak trigger. A broader coagulation panel may also be ordered when doctors need to understand bleeding risk, liver-related clotting changes, DIC, or anticoagulant effect.
Normal Range and Result Patterns
Antithrombin activity is usually reported as a percentage. A result of 100% means activity close to the average activity found in healthy reference samples. Many adult labs use a reference interval near 80% to 120%, 80% to 130%, or 75% to 135%. The exact range varies by method and laboratory.
Infants have lower antithrombin levels than older children and adults. This is normal and does not automatically mean deficiency. Pediatric results need age-specific reference ranges, especially in newborns and babies younger than 6 months.
| Result pattern | Common interpretation | What usually happens next |
|---|---|---|
| Within the lab range | Antithrombin function is not reduced at the time of testing. | Doctors look for other clotting risk factors if the clot history is concerning. |
| Mildly low | May reflect temporary illness, heparin effect, active clotting, liver disease, kidney protein loss, pregnancy-related changes, or early inherited deficiency. | Repeat testing is often needed when stable and away from interfering factors. |
| Clearly low, repeatedly | Raises concern for antithrombin deficiency, especially with personal or family clot history. | Antithrombin antigen testing and sometimes genetic testing may be used. |
| Very low | Can occur with severe inherited deficiency, DIC, severe liver disease, major protein loss, sepsis, or intensive care illness. | Needs urgent clinical interpretation because clotting and bleeding risks may both be present in critical illness. |
| High | Usually has limited clinical meaning by itself. | Often no specific follow-up unless related to treatment with antithrombin concentrate or another clinical issue. |
A single low result should not be used alone to diagnose inherited antithrombin deficiency. The result needs to fit the clinical situation and be confirmed. Repeat testing is especially important if the blood was drawn during an acute clot, during heparin therapy, during severe illness, or soon after surgery.
The activity result becomes more informative when paired with the antithrombin antigen test:
- Low activity and low antigen suggest type I deficiency, a quantitative problem where the body has too little antithrombin protein.
- Low activity and normal antigen suggest type II deficiency, a qualitative problem where antithrombin is present but does not work normally.
- Normal activity and normal antigen make clinically significant antithrombin deficiency less likely, though results still need context.
The antithrombin activity test does not diagnose a clot by itself. Imaging tests diagnose most clots. For example, ultrasound is used for suspected leg deep vein thrombosis, and CT pulmonary angiography or other imaging is used for suspected pulmonary embolism. A D-dimer blood test may help rule out a clot in selected low-risk situations, but it does not diagnose inherited antithrombin deficiency.
Causes of Low Antithrombin Activity
Low antithrombin activity means the measured anticoagulant function is reduced. The cause may be inherited, acquired, temporary, or a mix of several factors.
Temporary and acquired causes
Acquired causes are more common than inherited antithrombin deficiency. These causes lower antithrombin because the body uses it up, loses it, makes less of it, or is exposed to treatment that changes the result.
Common acquired causes include:
- Active blood clotting. A new or extensive clot can consume antithrombin.
- Heparin therapy. Heparin can temporarily lower antithrombin levels, and the clinical situation requiring heparin often adds other confounders.
- Disseminated intravascular coagulation. DIC causes widespread clotting activation and consumption of clotting factors and natural anticoagulants.
- Severe infection or sepsis. Inflammation and clotting activation can reduce antithrombin.
- Liver disease. The liver makes antithrombin, so reduced liver synthetic function can lower levels along with other clotting proteins.
- Nephrotic syndrome. Damaged kidneys can leak antithrombin into the urine along with albumin and other proteins.
- Protein-losing enteropathy. Loss of protein through the gut can lower antithrombin.
- Major surgery, trauma, burns, or critical illness. These states activate clotting, inflammation, and protein shifts.
- Asparaginase treatment. This cancer medicine can reduce liver production of several clotting-related proteins, including antithrombin.
- Pregnancy and postpartum complications. Pregnancy changes the clotting system, and complications such as severe preeclampsia, liver dysfunction, or DIC can lower antithrombin.
This is why timing matters. A low result during a clot-related hospital stay often answers a different question than a low result months later in a stable person. During an acute illness, antithrombin activity may show current clot-control stress rather than inherited baseline risk.
Inherited causes
Inherited antithrombin deficiency usually comes from a change in the SERPINC1 gene. The pattern is often autosomal dominant, meaning one altered copy can cause reduced antithrombin function and increased clot risk.
Inherited deficiency is often suspected when antithrombin activity stays low on repeat testing and the person has a strong pattern of venous clots. Family history is important but not perfect. Some relatives with the same deficiency may never have a clot, while others develop clots early or repeatedly.
Medication and testing effects
Anticoagulants can complicate clotting tests. Heparin is the most important medication issue for antithrombin because heparin works through antithrombin and can reduce measured levels. Direct oral anticoagulants may interfere with some coagulation assays depending on the method used, although antithrombin activity methods vary.
Warfarin does not lower antithrombin in the same way it lowers vitamin K-dependent proteins such as protein C, protein S, and factors II, VII, IX, and X. Still, clinicians often plan thrombophilia testing around anticoagulant use to avoid confusing results across a full panel.
If results are unexpected, the lab method matters. Some antithrombin assays are based on anti-Xa activity and others on anti-IIa activity. Certain rare antithrombin variants may be detected better by one method than another.
Inherited Antithrombin Deficiency
Inherited antithrombin deficiency is rare, but it is one of the stronger inherited risks for venous thromboembolism. The main concern is clot formation in deep veins and the lungs. These clots are called venous thromboembolism, or VTE.
A deep vein thrombosis often causes swelling, pain, warmth, or tenderness in one leg. A pulmonary embolism can cause shortness of breath, chest pain, coughing blood, fainting, rapid heartbeat, or sudden collapse. These symptoms need urgent medical care.
Inherited antithrombin deficiency is usually divided into two broad types:
| Type | Activity test | Antigen test | Meaning |
|---|---|---|---|
| Type I | Low | Low | The body has too little antithrombin protein. |
| Type II | Low | Often normal | The body makes antithrombin protein, but it does not work normally. |
Type II deficiency has subtypes. Some affect the active site, some affect the heparin-binding site, and some affect several functions. This distinction matters because clot risk and heparin response differ among variants. Heparin-binding site variants may show a different risk pattern from severe quantitative deficiency.
The risk is not the same for every person. Clot risk rises when antithrombin deficiency combines with triggers such as surgery, pregnancy, estrogen therapy, long flights, hospitalization, cancer, central venous catheters, severe infection, or prolonged immobility. Other inherited or acquired clotting risks can add to the total risk, including factor V Leiden, prothrombin gene mutation, antiphospholipid syndrome, high factor VIII, obesity, smoking, and active cancer.
Testing relatives is not automatic for every family, but it can be useful when a confirmed antithrombin deficiency is present. The most useful family testing starts with the known abnormality in the affected person. When a specific SERPINC1 variant is known, genetic testing may clarify which relatives inherited it. When no variant is known, activity and antigen testing may be used.
A person with confirmed inherited antithrombin deficiency does not always need lifelong anticoagulation after every scenario. Treatment length depends on clot history, whether the clot was provoked, bleeding risk, family history, deficiency type, and future risk exposures. Some people need long-term anticoagulation after recurrent or unprovoked VTE. Others need careful prevention during high-risk periods.
Pregnancy deserves special planning. Pregnancy and the first 6 weeks after delivery increase clot risk, and antithrombin deficiency adds to that risk. Women with known deficiency should discuss pregnancy planning, delivery, postpartum prevention, and medication choices with clinicians experienced in thrombosis and maternal care. Estrogen-containing birth control or hormone therapy may also need avoidance or careful risk review.
Antithrombin, Heparin, and Treatment Decisions
Heparin depends on antithrombin. When heparin binds antithrombin, antithrombin blocks clotting enzymes much faster. This is why low antithrombin can make heparin less effective, especially when the level is very low or when a person is critically ill.
Heparin resistance means a person needs more heparin than expected to reach a target anticoagulant effect. The target may be based on aPTT, activated clotting time, or anti-Xa activity, depending on the setting. Heparin resistance is most often discussed in intensive care, cardiac surgery, extracorporeal membrane oxygenation, major inflammation, and vascular procedures.
Low antithrombin is one possible cause. Other causes include high factor VIII, high fibrinogen, increased heparin-binding proteins, thrombocytosis, acute inflammation, and assay discordance. A person may look heparin resistant by aPTT even when the anti-Xa level shows enough heparin effect. This is why the aPTT result and anti-Xa result sometimes need to be interpreted together.
In practice, clinicians may respond to suspected heparin resistance by:
- Confirming the dose is appropriate for body weight and clinical indication.
- Checking whether the monitoring test is reliable in that patient’s condition.
- Ordering anti-Xa testing when aPTT results do not match the clinical picture.
- Measuring antithrombin activity if low antithrombin is suspected.
- Considering more heparin, antithrombin concentrate, plasma, or a direct thrombin inhibitor in selected settings.
These decisions are medical and situation-specific. Antithrombin concentrate is not a general supplement for mildly low outpatient results. It is usually reserved for defined high-risk settings, severe deficiency, selected pregnancy or delivery situations, major surgery, or heparin resistance when specialists believe replacement is appropriate.
Fresh frozen plasma contains antithrombin, but it also adds volume and transfusion risk. Antithrombin concentrate gives a more targeted dose. Direct thrombin inhibitors such as argatroban or bivalirudin work without antithrombin, so they may be considered when heparin cannot achieve the needed effect or when heparin is unsafe.
For people already taking long-term anticoagulants after a clot, the antithrombin result does not by itself decide whether medicine should stop. Doctors weigh clot recurrence risk against bleeding risk. A confirmed severe thrombophilia often pushes the decision toward stronger prevention, but the full history matters.
Follow-Up Testing and Next Steps
A low antithrombin activity result needs a careful second look before anyone labels it inherited deficiency. The best follow-up depends on why the test was ordered and what was happening when blood was drawn.
A typical follow-up plan may include:
- Repeating antithrombin activity when the person is stable
- Waiting until the acute clot or severe illness has resolved
- Reviewing heparin, direct oral anticoagulants, warfarin, asparaginase, estrogen therapy, and other medicines
- Checking liver function, kidney protein loss, albumin, urine protein, and signs of inflammation or DIC when relevant
- Ordering antithrombin antigen if activity remains low
- Testing close relatives when inherited deficiency is confirmed
- Considering SERPINC1 genetic testing when results remain abnormal or family planning decisions depend on clarity
The timing of repeat testing varies. Many clinicians wait several weeks after an acute clot or major illness. Testing is often clearer after the person is off heparin and no longer in an active inflammatory or consumptive state. If anticoagulation cannot be stopped safely, the clinician and laboratory can choose the least misleading strategy.
Antithrombin testing should not be read in isolation. A person with clot symptoms needs direct medical evaluation, not just blood marker interpretation. Leg ultrasound, chest imaging, oxygen levels, heart strain markers, and clinical severity guide urgent care. Blood tests support the investigation; they do not replace diagnosis.
When antithrombin deficiency is confirmed, prevention becomes practical. People often need a written plan for high-risk situations, including surgery, long hospital stays, pregnancy, postpartum recovery, leg immobilization, and long-distance travel. The plan may include anticoagulant medication, mechanical compression in the hospital, early walking, hydration, and avoidance of estrogen-containing medicines when risk is high.
Lifestyle does not correct inherited antithrombin deficiency, but it can reduce added clot risks. Useful steps include not smoking, maintaining mobility during travel, managing weight, treating sleep apnea if present, keeping chronic diseases controlled, and telling clinicians about the deficiency before surgery or pregnancy.
Family communication also matters. A confirmed inherited deficiency has implications for first-degree relatives, including parents, siblings, and children. Testing is most useful when it leads to prevention during high-risk periods, safer hormone choices, or better pregnancy planning.
Common Mistakes When Reading Results
A common mistake is assuming every low antithrombin result means a lifelong inherited disorder. In real practice, many low results are temporary or acquired. Acute clots, heparin therapy, sepsis, DIC, liver disease, kidney protein loss, and critical illness can all reduce antithrombin activity.
Another mistake is testing too early. A thrombophilia panel drawn during a hospital admission for a new clot can produce confusing results. Some findings may reflect the clot and its treatment rather than the person’s baseline clotting tendency. When the result will affect long-term decisions, repeat testing at the right time is often more reliable.
A third mistake is comparing results across labs as if the reference range is universal. Antithrombin activity depends on the assay method, calibration, age range, and reporting units. A value that looks borderline in one lab may fall inside another lab’s range. Always compare the result with the reference interval printed on the report.
A fourth mistake is focusing only on antithrombin while ignoring the whole clot story. A person’s risk depends on the type of clot, age at first clot, provoking triggers, family history, pregnancy history, cancer status, inflammatory disease, body weight, hormone use, and anticoagulant history.
A fifth mistake is confusing antithrombin with thrombin time or thrombin-antithrombin complexes. Antithrombin activity measures a natural anticoagulant protein. A thrombin time test measures how long it takes fibrinogen to form fibrin after thrombin is added. Thrombin-antithrombin complexes reflect recent thrombin generation and are a different marker.
Urgent symptoms should never wait for a thrombophilia appointment. Seek emergency care for sudden shortness of breath, chest pain, coughing blood, fainting, one-sided leg swelling with pain, sudden neurologic symptoms, or severe unexplained abdominal pain. Antithrombin results help explain risk, but acute clots need immediate diagnosis and treatment.
References
- American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing 2023 (Guideline)
- Thrombophilia testing: A British Society for Haematology guideline 2022 (Guideline)
- Recommendations for clinical laboratory testing for antithrombin deficiency; Communication from the SSC of the ISTH 2020 (Guidance)
- Venous thromboembolism risk in adults with hereditary thrombophilia: a systematic review and meta-analysis 2024 (Systematic Review)
- Troubleshooting heparin resistance 2024 (Review)
- How we treat severe inherited antithrombin deficiency: lessons from cases homozygous for the Budapest 3 variant 2025 (Review)
Disclaimer
This article is for education and does not replace care from a qualified health professional. Antithrombin results need interpretation with your symptoms, clot history, medications, pregnancy status, liver and kidney function, and timing of the blood draw. Seek urgent medical care for symptoms of a possible blood clot, pulmonary embolism, stroke, or severe bleeding.
